Global surveillance of in vitro activity of micafungin against Candida: A comparison with caspofungin by CLSI-recommended methods

Journal of Clinical Microbiology

Volumn 44, Issue 10, 2006, Pages 3533-3538

  Pfaller, M A ^a   Boyken, L ^a   Hollis, R J ^a   Messer, S A ^a   Tendolkar, S ^a   Diekema, D J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; MICAFUNGIN; ANTIFUNGAL AGENT; CYCLOPEPTIDE; LIPOPROTEIN;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; FUNGAL STRAIN; FUNGUS ISOLATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; DRUG EFFECT; LABORATORY; MICROBIOLOGICAL EXAMINATION; STANDARD;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; ISSATCHENKIA ORIENTALIS; KLUYVEROMYCES MARXIANUS; PICHIA GUILLIERMONDII;

ANTIFUNGAL AGENTS; CANDIDA; LABORATORIES; LIPOPROTEINS; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC;

EID: 33846512117     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00872-06     Document Type: Article

References (18)

1. Andes, D., and N. Safdar. 2005. Efficacy of micafungin for the treatment of candidemia. Eur. J. Clin. Microbiol. Infect. Dis. 24:662-664.
2. De Wet, N., A. Llanos-Cuentas, J. Suleiman, E. Baraldi, E. F. Krantz, M. Negra, and H. Diekmann-Berndt. 2004. A randomized double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin. Infect. Dis. 39:842-849.
3. Hazen, K. C., and S. A. Howell. 2003. Candida, Cryptococcus, and other yeasts of medical importance, p. 1693-1711. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. J. Yolken (ed.), Manual of clinical microbiology, 8th ed. ASM Press, Washington, D.C.
4. Hernandez, S., J. L. Lopez-Ribot, L. K. Najvar, D. I. McCarthy, R. Bocanegra, and J. R. Graybill. 2004. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. 48:1382-1383.
5. Jarvis, B., D. P. Figgitt, and L. J. Scott. 2004. Micafungin. Drugs 64:969-982.
6. Messer, S. A., D. J. Diekema, L. Boyken, S. Tendolkar, R. J. Hollis, and M. A. Pfaller. 2006. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J. Clin. Microbiol. 44:324-326.
7. Moudgal, V., T. Little, D. Boikov, and J. A. Vazquez. 2005. Multiechinocandin-and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother 49:767-769.
8. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard - second edition M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
9. Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella, A. Davison, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Lavediere, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Peman, S. Perea, J. R. Perfect, M. A. Pfaller, L. Prioa, J. H. Rex, M. G. Rinaldi, J. L. Rodriguez-Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock. 2004. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42:3475-3482.
10. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother 47:3149-3154.
11. Ostrosky-Zeichner, L., D. Kontoyiannis, J. Raffalli, K. M. Mullane, J. Vazquez, E. J. Anaissie, J. Lipton, P. Jacobs, J. H. Jansen van Rensburg, J. H. Rex, W. Lau, D. Facklam, and D. N. Buell. 2005. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis. 24:654-661.
12. Park, S., R. Kelly, J. Nielsen Kahn, J. Robles, M. J. Hsu, E. Register, W. Li, V. Vyas, H. Fan, G. Abruzzo, A. Flattery, C. Gill, G. Chrebet, S. A. Parent, M. Kurtz, H. Teppler, C. M. Douglas, and D. S. Perlin. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
13. Pfaller, M. A., and D. J. Diekema. 2004. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. 10(Suppl. 1):11-23.
14. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2004. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J. Clin. Microbiol. 42:3117-3119.
15. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2005. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 clinical isolates resistant to fluconazole. J. Clin. Microbiol. 43:5425-5427.
16. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2006. In vitro susceptibility of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. 44:760-763.
17. Pfaller, M. A., and D. J. Diekema. The epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev., in press.
18. van Burik, J. A., V. Ratanathorn, D. E. Stepan, C. B. Miller, J. H. Lipton, D. H. Vesole, N. Burin, D. A. Wall, J. W. Hiemenz, Y. Satoi, J. M. Lee, and T. J. Walsh for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. 2004. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 39:1407-1416.